Baxter International, Inc. (BAX) Presents Phase III HyQ Efficacy and Tolerability Data at American College of Allergy, Asthma and Immunology (ACAAI) Meeting
11/7/2011 8:12:01 AM
BOSTON--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX) today announced the presentation of its phase III study data for HyQ, an investigational combination immunoglobulin (IG) product for use in patients with primary immunodeficiencies (PI). The study evaluated efficacy and safety as well as the pharmacokinetics, infusion volumes, intervals, and rates compared to patients’ previous intravenous immunoglobulin (IGIV) administration. Results from the study were presented on Saturday, Nov. 5, during the American College of Allergy, Asthma and Immunology annual meeting in Boston.